



Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust

Johannes M. Giesinger^{a,1}, Jacobien M. Kieffer^{a,1}, Peter M. Fayers^{b,c}, Mogens Groenvold^{d,e}, Morten Aa. Petersen^d, Neil W. Scott^b, Mirjam A.G. Sprangers^f, Galina Velikova^g, Neil K. Aaronson^{a,*}, on behalf of the EORTC Quality of Life Group

^aDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

^bInstitute of Applied Health Sciences, University of Aberdeen, Foresterhill Road, AB25 2ZD Aberdeen, UK

^cDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Postboks 8905, N-7491 Trondheim, Norway

^dThe Research Unit, Department of Palliative Medicine, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark

^eDepartment of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1014 Copenhagen, Denmark

^fDepartment of Medical Psychology, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

^gLeeds Institute of Cancer and Pathology, St James's Institute of Oncology, University of Leeds, Beckett Street, LS9 7TF Leeds, UK

Accepted 21 August 2015; Published online 28 September 2015

Abstract

Objective: To further evaluate the higher order measurement structure of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), with the aim of generating a summary score.

Study Design and Setting: Using pretreatment QLQ-C30 data (N = 3,282), we conducted confirmatory factor analyses to test seven previously evaluated higher order models. We compared the summary score(s) derived from the best performing higher order model with the original QLQ-C30 scale scores, using tumor stage, performance status, and change over time (N = 244) as grouping variables.

Results: Although all models showed acceptable fit, we continued in the interest of parsimony with known-groups validity and responsiveness analyses using a summary score derived from the single higher order factor model. The validity and responsiveness of this QLQ-C30 summary score was equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores.

Conclusion: Our results provide empirical support for a measurement model for the QLQ-C30 yielding a single summary score. The availability of this summary score can avoid problems with potential type I errors that arise because of multiple testing when making comparisons based on the 15 outcomes generated by this questionnaire and may reduce sample size requirements for health-related quality of life studies using the QLQ-C30 questionnaire when an overall summary score is a relevant primary outcome. © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Health-related quality of life; Questionnaires; EORTC QLQ-C30; Measurement model; Higher order factor scores; Confirmatory factor analysis

1. Introduction

Patient-reported outcome measures (PROMs) are currently seen as important outcomes in both observational studies and clinical trials. They represent the patients' voice in determining the burden of disease and its treatment. One

of the most widely used PROMs in oncology is the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) [1]. The QLQ-C30 is a multidimensional health-related quality of life (HRQOL) questionnaire composed of six functional scales, three symptom scales, and a number of additional single item scales (15 outcomes, in total).

Although the QLQ-C30 provides a wealth of information about the HRQOL of patients, it also presents an analytic challenge because of the multiple outcomes it generates, and the concomitant risk of committing a type I error due to multiple testing [1,2]. In some studies, it is

Funding: The work of J.M.G. was supported by a grant from the Austrian Science Fund (FWF J3353).

¹ Shared first authorship.

* Corresponding author. Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel.: +31-20-5122481; fax: +31-20-5122322.

E-mail address: n.aaronson@nki.nl (N.K. Aaronson).

<http://dx.doi.org/10.1016/j.jclinepi.2015.08.007>

0895-4356/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

What is new?

Key findings

- We found a robust single higher order factor model to be the best performing measurement model for the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
- The resulting QLQ-C30 summary score exhibits equal or superior known-groups validity and responsiveness to change over time as compared to the individual QLQ-C30 scales.

What this adds to what was known?

- The results support the robustness of a single-factor higher order measurement model for the QLQ-C30.
- The validity and responsiveness of the QLQ-C30 summary score is equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores.

What is the implication and what should change now?

- The EORTC Quality of Life Group recommends using the QLQ-C30 summary score to supplement the 15-outcome profile generated by the QLQ-C30.
- The availability of a summary score can facilitate more reliable hypothesis testing analyzing QLQ-C30 data.
- If the QLQ-C30 summary score is chosen as the primary focus of a study, then its use can reduce the risk of type I errors that can occur when making comparisons based on the original 15 outcomes generated by the QLQ-C30. Thus, it may be possible to reduce sample size requirements for health-related quality of life studies using the QLQ-C30 questionnaire.

possible to reduce the number of statistical tests performed by defining a limited set of QLQ-C30 scales that are of primary interest. Preferably this is done on an a priori basis to avoid selective, post-hoc reporting of results [3,4]. However, in many studies, it may be difficult to prespecify which QLQ-C30 scales are of most interest. In such cases, investigators frequently rely on the two-item scale assessing overall quality of life [5–8].

The disadvantage of this very brief two-item overall quality of life scale is that it may have less measurement precision than is desired for detecting group differences over time. In addition, it may not be a conceptually

appropriate summary of the QLQ-C30, which contains a relatively large number of symptom scales and items [9,10].

On the basis of such considerations, Hinz et al. and Nordin et al. introduced and investigated summary scores for the QLQ-C30. Hinz et al. [11] used a total score derived from summing up all 30 items of the questionnaire and two separate summary scores based on the sum of all items of the functioning domains and of the symptom domains, respectively. Nordin et al. [12] investigated the known-groups validity of the two-item global quality of life scale and three alternative scoring algorithms for the QLQ-C30 based on (1) the 15 QLQ-C30 scale means; (2) the sum of all individual QLQ-C30 items (except for the item on financial problems); and (3) the sum of the scales assessing physical function, emotional function, quality of life, fatigue, nausea/vomiting, pain, appetite, and diarrhea. For all proposed summary measures, change was categorized in one way or the other into improved, unchanged, and worse. The three alternative scoring approaches performed considerably better than the original, two-item quality of life scale. Although this study documented that the QLQ-C30 global quality of life scale may not be particularly well suited for detecting changes between patient groups and/or changes over time, the alternative summary scoring algorithms proposed were generated in an ad hoc manner, without rigorous empirical testing of hypothesized measurement models.

Cognizant of the need to have a solid empirical basis for any proposed higher summary score for the QLQ-C30, Gundy et al. [10] used structural equation modeling to test seven alternative higher order measurement models for the QLQ-C30. All models exhibited a moderate-to-good model-data fit. The model that showed the best statistical fit (slightly better than the other models) was a two-factor model of physical and mental health. This is conceptually similar to the SF-36 Health Survey component scores, and the factor structure of the PROMIS domain mapping project [10,13–16]. Although appealing conceptually, Gundy et al. questioned if this advantage outweighs the model's relatively complex nature, and if perhaps a more parsimonious and simpler model would be more suitable.

The aims of the present study were to (1) identify the best performing higher order model among those suggested by Gundy et al. [10]; (2) test the validity and responsiveness of the best performing higher order factor score(s) as compared to that of the underlying individual scales of the QLQ-C30; and (3) develop an additional scoring algorithm for summary score(s) for the QLQ-C30 on the basis of a higher order measurement model.

2. Methods

2.1. Data source

The QLQ-C30 data used for these analyses were collected originally for the EORTC Quality of Life Cross-

Cultural Meta-Analysis Group (see Appendix at www.jclinepi.com) and have been described in detail elsewhere [10,17,18]. Briefly, the pooled database was formed from 124 individual data sets from 48 countries. In addition to the QLQ-C30, the data set also incorporated patient and clinical characteristics, including age, sex, country, language of administration, primary disease site, and stage of disease. The database consisted of 38,000 respondents, of whom more than 30,000 completed baseline (pretreatment) questionnaires. Of these 30,000 respondents, 9,044 completed the most recent version (3.0) of the QLQ-C30 [10]. For their study, Gundy et al. [10] selected a 50% random sample of the 9,044 respondents who completed the QLQ-C30, version 3.0. In the present study, we used the remaining 50% of that sample but restricted ourselves to those patients for whom tumor stage was known ($N = 3,282$). For the longitudinal analysis, we included patients for whom both pretreatment and on-treatment QLQ-C30 data and information on the type of treatment received were available ($N = 811$).

2.2. The EORTC QLQ-C30

The 30-item EORTC QLQ-C30 version 3.0 [1,2] consists of five multi-item function scales (physical [PF], role [RF], cognitive [CF], emotional [EF], and social [SF]), three multi-item symptom scales (fatigue [FA], nausea and vomiting [NV], and pain [PA]), six single-item symptom scales (dyspnea [DY], insomnia [SL], appetite loss [AP], constipation [CO], diarrhea [DI], and financial impact [FI]), and a two-item global quality of life scale (QL).

The questionnaire has a 1-week time frame and uses a four-point response format (“not at all,” “a little,” “quite a bit,” and “very much”), with the exception of the global QL scale, which has a seven-point response format. For the functioning and the QL scales, a higher score indicates better health. For the symptoms scales, a higher score indicates a higher level of symptom burden.

2.3. Models tested

In the current analysis, we tested the seven HRQOL higher order measurement models evaluated by Gundy et al. [10]. For a graphical representation of the models, see Fig. 1.

- (1) The *Standard* 14 dimensional QLQ-C30 model, the original measurement model of the QLQ-C30, which formed the basis for all of the other models described here.
- (2) The two-factor, *Physical health* and *Mental health* model, in which the original QLQ-C30 scales RF, SF, FA, PA, and SL load on both the mental as well as the physical higher order factor. The remaining scales load only on the physical higher order factor (PF, NV, DY, AP, CO, and DI scale) or on the mental higher-order factor (EF and CF scale).

- (3) The *Physical burden and Mental function* model, in which PF, FA, NV, PA, DY, SL, AP, CO, and DI load on the *Physical burden* factor. The functional scales EF and CF load on the *Mental function* factor, and RF and SF load on both factors.
- (4) The *Symptom burden and Function* model [19], in which PF, SF, RF, CF, and EF load on *Function*, and FA, NV, PA, DY, SL, AP, CO, and DI load on *Burden*.
- (5) The one-factor HRQOL model [20], in which all original QLQ-C30 scales (with the exception of the QL scale) load on HRQOL.
- (6) & (7) The Formative *Symptom burden and Function* model [21,22], in which FA, NV, PA, DY, SL, AP, CO, and DI function are seen as formative indicators of *Burden*, and PF, SF, RF, CF, and EF function as reflective indicators of *Function*. In model 6, the weights of the formative scales are estimated freely, and in model 7, they are fixed to 1.0.

In all the previously mentioned models, FI is omitted, and the QL scale is correlated with, but not subsumed by any higher order factor. This is in line with the approach followed by Gundy et al. [10]. However, for completeness, we also show in Fig. 1 an 8th model—a one-factor model using all 30 items of the QLQ-C30.

2.4. Statistical analyses

Descriptive statistics were used to characterize the sample in terms of sociodemographic and clinical variables. For replication purposes, the modeling procedures were identical to those used in the study of Gundy et al. [10]. In short, we used pretreatment QLQ-C30 data and carried out higher order confirmatory factor analyses (CFAs) in Mplus, version 6.12 [23]. We modeled the original QLQ-C30 subscales as first-order factors. The QL scale was also modeled as a first-order factor and was allowed to correlate with all other higher order factors but remained distinct from them. To be able to identify the models, we fixed one of the item loadings to a value of 1.0. Both loadings of items corresponding to the QL latent variable were also fixed. As in the study of Gundy et al. [10], we fixed the residual variances for the single-item first-order factors to be equal, at 20% of the total variance for these factors, on the basis of test–retest correlations reported elsewhere [24].

We used pair-wise deletion, and a weighted least squares estimator with adjustment for means and variance, which takes into account deviations from normality [25,26]. To test goodness of fit, we used the Comparative Fit Index and the Tucker-Lewis Index. For both, values ≥ 0.95 indicate a good fit, and values > 0.90 an acceptable fit [27]. We also used the Root Mean Square Error of Approximation as an indicator of model fit, with values < 0.05 indicating a good fit, and between 0.05 and 0.08 an




Fig. 1. Higher order models for the EORTC QLQ-C30 (models 1–7 was taken from Gundy et al., model 8 was created ad hoc). AP, appetite loss; CF, cognitive function; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire Core 30; FA, fatigue; FI, financial impact; HRQOL, health-related quality of life; NV, nausea and vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; SF, social function; SL, insomnia.

acceptable fit [28]. These fit indices are sensitive to model complexity, paradoxically generating better fit indices for less complex models. Therefore, selected models were required to have at least an acceptable fit according to the

threshold values. Furthermore, all standardized factor loadings were required to be greater than 0.4 and statistically significant [29]. Given that the data set included different sources of data, we adjusted for the possible variability in

populations and procedures by taking cluster sampling into account [10].

We used analysis of variance (ANOVA) to examine known-groups validity, that is, the ability of the factor score(s) derived from the best fitting higher order model, and of the original QLQ-C30 scale scores to distinguish between groups known to be clinically different. We used tumor stage (local vs. advanced) and performance status (Karnofsky score 0-80 vs. 90-100) as grouping variables. We evaluated responsiveness by comparing pretreatment versus on-treatment QLQ-C30 scores. We calculated effect sizes (ESs) using Cohen's *d* statistic (mean difference divided by the pooled standard deviation). These provide a distribution-based estimate of the magnitude of mean differences, where an ES of 0.2 is considered small, 0.5 moderate, and 0.8 large [30].

We also generated relative validity (RV) estimates by comparing the performance of higher order factor score(s) with the original QLQ-C30 scale scores. The RV is the ratio of the *F*-statistics derived from analysis of variance comparing groups or time points. The RV indicates the relative difference in sample size needed to detect a statistically significant difference in mean scores using the two measures. More specifically, if the *F*-statistic ratio, in which the *F*-statistic of the comparative scale is the numerator and the *F*-statistic of a reference scale is the denominator ($F_{\text{comp}}/F_{\text{ref}}$), is greater than 1, then the comparative measure is judged as performing better than the reference measure. In the context of RV, "better performance" means that a smaller sample size is required to detect a mean difference [31,32].

3. Results

3.1. Patient characteristics

Pretreatment data were available from 3,282 patients (53.0% men; mean age 58.9 years). The most frequent diagnoses were head-and-neck cancer (23.7%), breast cancer (17.4%), and prostate cancer (13.0%). Most patients (72.4%) had an advanced tumor stage (UICC stage III or IV). Pretreatment Karnofsky performance status data were available for 53.5% of the sample (mean = 85.6; SD 15.7). For further details, see Table 1.

Both pretreatment and on-treatment QLQ-C30 data and information on the type of treatment were available for 811 patients (73.2% men; mean age 61.3 years). Of these patients, 35.1% were treated with chemotherapy, 30.0% with radiotherapy, 28.6% had surgery, and 6.3% had another type of treatment. Most common diagnoses were head-and-neck cancer (31.6%), prostate cancer (34.6%), and ovarian cancer (11.0%).

3.2. Modeling

Table 2 presents the fit indices for the seven models tested. All models showed an acceptable fit, with the

Table 1. Patient characteristics at baseline (before treatment; *n* = 3,282)

| | |
|--------------------------------------|-------------|
| Age | |
| Mean (SD) | 58.9 (12.7) |
| Unknown | 12.9% |
| Sex | |
| Men | 53.0% |
| Women | 43.4% |
| Unknown | 3.6% |
| Karnofsky status | |
| Mean (SD) | 85.6 (15.7) |
| Unknown | 46.6% |
| Diagnosis | |
| Head and neck | 23.7% |
| Breast | 17.4% |
| Prostate | 13.0% |
| Esophagus/stomach | 12.6% |
| Gynecological | 11.1% |
| Lung | 7.2% |
| Myeloma | 3.0% |
| Colorectal | 2.6% |
| Testicular | 2.6% |
| Leukemia | 2.1% |
| Other | 4.7% |
| Stage | |
| Locoregional (I and II) | 27.6% |
| Advanced (III and IV and recurrence) | 72.4% |
| Country | |
| Norway | 14.7% |
| Sri Lanka | 13.2% |
| United Kingdom | 8.9% |
| Spain | 8.3% |
| Germany | 8.2% |
| Netherlands | 6.1% |
| Sweden | 5.5% |
| France | 5.2% |
| Belgium | 4.4% |
| Canada | 3.1% |
| USA | 3.0% |
| Poland | 2.6% |
| Turkey | 2.6% |
| Other | 14.1% |
| Study type | |
| RCT | 30.8% |
| Observational | 31.8% |
| Psychometric | 35.1% |
| Unknown | 2.4% |

Abbreviations: SD, standard deviation; RCT, randomized-controlled trial.

standard model showing a good fit. With the exception of the standard model, models 2 and 3 showed the best fit. However, examination of the parameter estimates in model 2 indicated that the standardized factor loadings for the SL scale on physical health, and for the RF, FA, and PA scale on mental health, were below the 0.4 threshold (−0.02, −0.16, 0.15, and 0.16, respectively). For model 3, the standardized factor loading of RF was below 0.4 (−0.255). These low factor loadings indicate that these first-order factors might have to be excluded from the model. In models 4 and 5, all factor loadings were statistically significant and of moderate to strong magnitude, providing support for the models. All

Table 2. Approximate goodness-of-fit indices for the higher order measurement models of the EORTC QLQ-C30

| Model | CFI | TLI | RMSEA | Remarks |
|---|-------|-------|-------|---|
| 1. Standard | 0.969 | 0.979 | 0.047 | |
| 2. Physical/mental health and QL | 0.943 | 0.971 | 0.056 | Correlation between physical health and mental health = 0.786 |
| 3. Physical burden/mental function and QL | 0.944 | 0.970 | 0.057 | Correlation between physical burden and mental function = 0.424 |
| 4. Symptom burden, function and QL | 0.932 | 0.966 | 0.061 | Correlation between burden and function = 0.564 |
| 5. HRQOL and QL | 0.931 | 0.965 | 0.061 | |
| 6. Formative symptom burden (free weights), function, and QL | 0.938 | 0.966 | 0.061 | Correlation between formative burden and function = 0.953 |
| 7. Formative symptom burden (fixed weights), function, and QL | 0.934 | 0.964 | 0.062 | Correlation between formative burden and function = 0.938 |
| 8. HRQOL including QL and FI | 0.919 | 0.966 | 0.055 | |

Abbreviations: CFI, Comparative Fit Index; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; FI, financial impact; HRQOL, health-related quality of life; RMSEA, root mean square error of approximation; TLI, Tucker-Lewis Index; QL, global quality of life.

standardized factor loadings for the function factor of model 6 were greater than 0.4 and statistically significant. However, for the formative symptom burden factor, only FA had a standardized regression weight greater than 0.4. When fixing the weights for the formative scales on the burden factor (model 7), all standardized regression weights were far below the 0.4 threshold. In addition, in both models, we found large correlations between the higher order factors (Table 2), and in model 7, we found a negative residual variance for item 19 (“Did pain interfere with your daily activities?”; -0.009), which could indicate identification problems suggesting the inappropriateness of the model.

As in Gundy’s study, the modification indices (that estimate the decrease in model chi square when freeing a fixed parameter [33]) showed that item 22 (“Did you worry?”) caused problems when fitting the models. We also observed that the EF scale was associated with other scales not captured by the fitted models.

When taking both fit indices and magnitude of factor loadings into account, models 4 and 5 were the most promising. In the interest of parsimony and for conceptual reasons (ie, function scales such as EF and CF include items assessing symptoms), we decided to continue the analysis with the less complex, single higher-order factor model 5 (Fig. 1 and Table 3).

Having selected the single-factor HRQOL model, we investigated further if the model fit would be acceptable if we were to include all 15 scales of the QLQ-C30 in the model, including the global QL scale and the FI scale that were excluded a priori by Gundy et al. (model 8 in Fig. 1). Although this model showed an acceptable fit (Table 2) and statistically significant standardized factor loadings greater than 0.4, the results confirmed identification problems (ie, a negative residual variance for one of the items (“Have you felt nauseated?”; -0.010), indicating that the model does not work well.)

On the basis of these results, we generated a QLQ-C30 summary score, calculated as the mean of the combined 13 QLQ-C30 scale scores included in model 5 (excluding FI and QL). For this purpose, all included scale scores were

reversed so that higher scores represent better outcomes (ie, better functioning or fewer symptoms).

3.3. Known-group comparisons and responsiveness

We investigated the ability of the QLQ-C30 summary score to distinguish between groups formed on the basis of tumor stage (stage I–II vs. III–IV) and Karnofsky performance status (0–80 vs. 90–100), as compared to the original 15 scale scores of the QLQ-C30. To calculate RV, we used the QLQ-C30 summary score as the reference value (ie, the denominator of this ratio).

Using tumor stage (Table 4) as the grouping variable, the QLQ-C30 summary score showed the highest ES (-0.65) and RV, together with the fatigue scale (ES = 0.64,

Table 3. (Un)standardized factor loadings for first-order factors (EORTC QLQ-C30 scales) on the HRQOL higher order factor

| Scale | HRQOL higher order factor | |
|-------|--------------------------------|------------------------------|
| | Unstandardized factor loadings | Standardized factor loadings |
| PF | 1.000 ^b | 0.778 ^a |
| SF | 1.044 | 0.837 ^a |
| RF | 1.323 | 0.906 ^a |
| EF | 0.782 | 0.602 ^a |
| CF | 1.079 | 0.811 ^a |
| FA | 1.329 | 0.953 ^a |
| NV | 1.010 | 0.667 ^a |
| PA | 1.033 | 0.798 ^a |
| DY | 0.863 | 0.785 ^a |
| SL | 0.781 | 0.753 ^a |
| AP | 1.121 | 0.854 ^a |
| CO | 0.766 | 0.747 ^a |
| DI | 0.552 | 0.629 ^a |

Abbreviations: AP, appetite loss; CF, cognitive function; CFA, confirmatory factor analysis; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; FA, fatigue; HRQOL, health-related quality of life; NV, nausea and vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; SF, social function; SL, insomnia.

^a $P < 0.01$.

^b Unstandardized factor loadings were fixed to 1.0 for model identification.

Table 4. Effect sizes and relative validities for the scales and summary score of the EORTC QLQ-C30 using the known-group comparison for tumor stage

| Scale | Stage I–II, N = 907 | | Stage III–IV, N = 2,375 | | ES | RV |
|---------------|------------------------|------|----------------------------|------|-------|-------------------|
| | Mean | SD | Mean | SD | | |
| Summary score | 84.2 | 14.3 | 73.0 | 18.3 | −0.65 | 1.00 ^a |
| PF | 84.4 | 18.7 | 73.6 | 24.1 | −0.47 | 0.53 |
| SF | 86.6 | 21.0 | 69.4 | 30.7 | −0.61 | 0.87 |
| RF | 81.5 | 26.4 | 61.3 | 35.5 | −0.61 | 0.88 |
| EF | 76.0 | 23.1 | 69.6 | 24.3 | −0.27 | 0.17 |
| CF | 86.2 | 19.0 | 80.6 | 22.4 | −0.26 | 0.16 |
| QL | 66.7 | 23.1 | 55.4 | 24.6 | −0.47 | 0.51 |
| FA | 23.5 | 23.5 | 40.9 | 28.7 | 0.64 | 0.97 |
| NV | 5.4 | 14.2 | 12.4 | 21.4 | 0.36 | 0.30 |
| PA | 18.0 | 23.2 | 35.4 | 31.9 | 0.58 | 0.81 |
| DY | 14.6 | 24.8 | 22.8 | 29.4 | 0.29 | 0.20 |
| SL | 24.2 | 29.8 | 31.6 | 32.7 | 0.23 | 0.13 |
| AP | 13.5 | 25.0 | 28.7 | 34.8 | 0.47 | 0.53 |
| CO | 13.5 | 23.3 | 23.7 | 32.0 | 0.34 | 0.27 |
| DI | 7.5 | 18.4 | 10.6 | 22.6 | 0.14 | 0.05 |

Abbreviations: AP, appetite loss; CF, cognitive function; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue; NV, nausea and vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; RV, Relative validity: performance of the measures indicated as the ratio of the sample sizes required to detect a mean difference with the measures being compared (ie, scores less than 1.0 indicate better performance for the QLQ-C30 summary score); SD, standard deviation; SF, social function; SL, insomnia.

^a Reference score for calculating relative validity (ie, the ratio of the F-statistics of the comparative score [numerator] and the reference score [denominator]).

RV = 0.97). The two-item global QL scale showed a substantially lower ES of −0.47 and an RV of 0.51 when compared to the QLQ-C30 summary score. Mean differences between patients with stage I–II and stage III–IV were statistically significant for all scales (all *P* values < 0.001).

A similar pattern of results was found using performance status as the grouping variable (Table 5). In this comparison, the QLQ-C30 summary score had the highest ES (1.34), with the Role Functioning scale (ES = 1.32, RV = 0.97) and the Physical Functioning scale (ES = 1.29, RV = 0.93) performing nearly as well. Again, the global QL scale was less discriminating, with an ES of 1.10 and an RV of 0.67. Mean differences between patients with a low and high performance status (0–80 vs. 90–100) were again statistically significant for all scales (all *P* values < 0.001).

In the longitudinal responsiveness analysis, only small changes in HRQOL were observed in the 811 patients with known-treatment type and pretreatment and on-treatment QLQ-C30 data. With the exception of nausea/vomiting (ES = 0.34), all mean changes had ES's less than 0.30 (with the lowest change found for global QL:

Table 5. Effect sizes and relative validities for the scales and summary score of the EORTC QLQ-C30 using the known-group comparison for performance status

| Scale | Karnofsky, 0–80, N = 693 | | Karnofsky, 90–100, N = 1,059 | | ES | RV |
|---------------|--------------------------------|------|------------------------------------|------|-------|-------------------|
| | Mean | SD | Mean | SD | | |
| Summary score | 62.0 | 18.1 | 83.7 | 14.8 | 1.34 | 1.00 ^a |
| PF | 60.5 | 25.6 | 87.0 | 16.4 | 1.29 | 0.93 |
| SF | 57.4 | 33.1 | 84.1 | 23.4 | 0.97 | 0.52 |
| RF | 39.7 | 36.4 | 80.8 | 27.2 | 1.32 | 0.97 |
| EF | 67.5 | 25.8 | 75.2 | 23.4 | 0.32 | 0.06 |
| CF | 72.5 | 26.4 | 87.2 | 18.8 | 0.66 | 0.25 |
| QL | 43.8 | 23.1 | 68.5 | 22.1 | 1.10 | 0.67 |
| FA | 56.5 | 28.5 | 25.3 | 25.1 | −1.18 | 0.77 |
| NV | 20.2 | 26.8 | 6.2 | 15.0 | −0.68 | 0.26 |
| PA | 50.6 | 34.5 | 19.3 | 25.4 | −1.07 | 0.63 |
| DY | 33.1 | 32.5 | 15.0 | 24.4 | −0.65 | 0.24 |
| SL | 35.5 | 34.9 | 25.0 | 30.4 | −0.33 | 0.06 |
| AP | 43.5 | 38.7 | 12.7 | 24.7 | −0.99 | 0.55 |
| CO | 35.6 | 35.9 | 13.7 | 25.7 | −0.73 | 0.29 |
| DI | 15.6 | 27.8 | 8.5 | 19.8 | −0.30 | 0.05 |

Abbreviations: AP, appetite loss; CF, cognitive function; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue; NV, nausea and vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; RV, Relative validity: performance of the measures indicated as the ratio of the sample sizes required to detect a mean difference with the measures being compared (ie, scores less than 1.0 indicate better performance for the QLQ-C30 summary score); SD, standard deviation; SF, social function; SL, insomnia.

^a Reference score for calculating relative validity (ie, the ratio of the F-statistics of the comparative score [numerator] and the reference score [denominator]).

ES = 0.01). On the basis of these findings, we conducted further responsiveness analyses for the radiotherapy group only (*n* = 244), as this group exhibited the most pronounced score changes between the pretreatment and on-treatment assessment (Table 6) and thus was considered the most suitable subsample for this type of analysis. In this radiotherapy group, the mean age was 65.6 years and 74.6% were female. Most common diagnoses were head-and-neck cancer (33.3%), prostate cancer (37.9%), and breast cancer (14.8%).

The comparison of patients before and during radiotherapy showed the highest ES's for individual symptom scale scores (appetite loss ES = 0.71; diarrhea ES = 0.68; nausea/vomiting, ES = 0.66). The QLQ-C30 summary score had a somewhat lower ES (−0.59) and RV (1.00) compared to that of appetite loss RV (1.07), but higher RV than that of nausea/vomiting (RV = 0.81) and diarrhea (RV = 0.67). The global QL scale exhibited substantially poorer responsiveness (ES = −0.32, RV = 0.19). Changes in mean scores between the two time points were statistically significant for all scales (all *P* values < 0.001).

Table 6. Effect sizes and relative validities for the scales and summary score of the EORTC QLQ-C30 for responsiveness to change in patients before and during radiotherapy

| Scale | Pretreatment, N = 244 | | On-treatment, N = 244 | | ES | RV |
|---------------|--------------------------|------|--------------------------|------|-------|-------------------|
| | Mean | SD | Mean | SD | | |
| Summary score | 78.8 | 17.1 | 64.6 | 29.5 | −0.59 | 1.00 ^a |
| PF | 75.1 | 25.5 | 65.8 | 32.6 | −0.32 | 0.47 |
| SF | 79.4 | 26.6 | 67.7 | 35.3 | −0.37 | 0.35 |
| RF | 71.0 | 36.2 | 61.0 | 36.8 | −0.27 | 0.23 |
| EF | 75.7 | 24.7 | 62.7 | 31.9 | −0.46 | 0.40 |
| CF | 83.3 | 23.3 | 68.4 | 33.9 | −0.51 | 0.61 |
| QL | 59.5 | 24.6 | 51.8 | 23.6 | −0.32 | 0.19 |
| FA | 30.0 | 27.4 | 45.0 | 31.4 | 0.51 | 0.72 |
| NV | 7.8 | 17.4 | 25.7 | 34.5 | 0.66 | 0.81 |
| PA | 31.9 | 33.0 | 41.2 | 33.9 | 0.28 | 0.24 |
| DY | 19.1 | 27.9 | 30.2 | 35.8 | 0.35 | 0.28 |
| SL | 27.1 | 31.2 | 41.2 | 35.3 | 0.42 | 0.34 |
| AP | 15.7 | 26.9 | 39.4 | 38.6 | 0.71 | 1.07 |
| CO | 20.6 | 31.1 | 36.8 | 37.1 | 0.47 | 0.46 |
| DI | 7.2 | 17.8 | 26.3 | 35.4 | 0.68 | 0.67 |

Abbreviations: AP, appetite loss; CF, cognitive function; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional function; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; ES, effect size; FA, fatigue; NV, nausea and vomiting; PA, pain; PF, physical function; QL, global quality of life; RF, role function; RV, relative validity: performance of the measures indicated as the ratio of the sample sizes required to detect a mean difference with the measures being compared (ie, scores less than 1.0 indicate better performance for the QLQ-C30 summary score); SD, standard deviation; SF, social function; SL, insomnia.

^a Reference score for calculating relative validity (ie, the ratio of the F-statistics of the comparative score [numerator] and the reference score [denominator]).

4. Discussion

From the higher order HRQOL models originally introduced by Gundy et al. [10], we have identified a single higher-order factor model based on 27 of the 30 items of the QLQ-C30 (excluding QL and FI) that exhibits good model-data fit. The QLQ-C30 summary score derived from this model is better than the original QLQ-C30 scales in discriminating between groups known to be clinically different. On the basis of the total patient sample, we were unable to demonstrate that the summary scale performed equally well or better than the individual QLQ-C30 scales in terms of responsiveness to change over time. This was likely due to the fact that, for the entire sample, it was difficult to detect significant change in QLQ-C30 scores over time, regardless of which measure was used (the summary scale or the original, individual scales). We were, however, able to identify a subsample of patients, those receiving radiotherapy, where significant change in the original QLQ-C30 scale scores was observed. The observed responsiveness in the radiotherapy setting is something that one would expect a priori. In the context of that subgroup analysis, the responsiveness of the summary scale was equal to

or better than that of the original, individual scales of the questionnaire.

The availability of this summary score for the QLQ-C30 provides a psychometrically more robust alternative to the two-item overall QL scale score that is used frequently as the primary HRQOL endpoint in observational studies and clinical trials in oncology settings. Although model-data fit was acceptable to good for all models proposed by Gundy et al. [10], most two-factor models fell short of the additional criterion we posed in this analysis, namely, requiring the loadings to be greater than 0.40. The single-factor HRQOL model including QL and FI exhibited acceptable fit. Although this model may seem intuitively attractive, it exhibited identification problems. These identification problems reflect the remark of Gundy et al. [10] that including the two-item quality of life scale as an explicit element of a higher order model is problematic conceptually, and that the FI item should be omitted because it is often excluded from analysis and reporting of QLQ-C30 results. As pointed out in the results section, the single higher order factor model, excluding QL and FI, was preferred for statistical and conceptual reasons. It also deals best with the potential problem of alpha error inflation. In known-group comparisons and analysis of responsiveness the newly developed QLQ-C30 summary score outperformed or performed equally well as the individual QLQ-C30 scales.

In an earlier attempt to develop a summary score for the QLQ-C30, Hinz et al. [11] compared a functioning and symptom summary score (comparable to our model 4) against a single summary score comprising all 30 items. On the basis of known-group comparisons, a single summary score was favored. As noted in the introduction, Nordin et al. [12] found that the two-item QLQ-C30 quality of life scale was not sensitive enough to detect group differences over time as opposed to three alternative summary measures based on all or part of the QLQ-C30. However, neither Hinz et al. nor Nordin et al. based their proposed, alternative scoring algorithms on explicit conceptual considerations; nor did they conduct formal testing of measurement models using structural equation modeling or other statistical techniques. In our view, a particular problem with the scoring algorithm proposed by Hinz et al. is that it is based on the scores of all individual items of the QLQ-C30, rather than on scale scores. By doing so, they implicitly weighted the summary score such that those scales with more items contributed more to the summary score than those scales with fewer items. In contrast, our scoring approach calculates the scale scores as the mean of the summed items in a scale rather than as the sum of the items in that scale. In this way, all scales are given equal weight (importance). This scoring algorithm reflects the EORTC Quality of Life Group's decision to weigh all QLQ-C30 scales equally, regardless of the number of items in a scale. The fact that some QLQ-C30 scales contain more items than others reflects the complexity of the domain being

assessed (eg, emotional functioning being a more complex domain than constipation), but not the importance attached to the domain. Finally, as we noted in the methods section, we initially examined an additional, 8th measurement model for the QLQ-C30 that included all 15 scales. However, those data could not be fitted into a single higher order factor model.

The FACT-G, another widely used HRQOL questionnaire, also has a summary (or total) score. To the best of our knowledge, the FACT-G total score is not based on the results of higher order CFA. Nonetheless, known-group comparisons and analyses of responsiveness comparing the FACT-G total score to its individual scales showed similar results to those of our study comparing the QLQ-C30 summary score with the individual QLQ-C30 scale scores [34,35].

King et al. [5] reported that the FACT-G total score outperformed the two-item QLQ-C30 global QL scale score in terms of both RV (0.31) and responsiveness to change over time. In our analysis of responsiveness, the QLQ-C30 Global QL scale had an RV of only 0.18 when compared to the QLQ-C30 summary score, suggesting a major gain in responsiveness when using the summary score. These results are not surprising given that the FACT-G total score and the QLQ-C30 summary score summarize data from a larger set of items (both 27 items), whereas the EORTC global QL scale score is based on only two items. It would be of interest to compare the RV and responsiveness of the FACT-G total score and the QLQ-C30 summary score.

The generalizability of our results is enhanced by the fact that we had a very large and heterogeneous sample of patients drawn from a number of participating countries. There was some imbalance in the sample with regard to diagnosis. However, as diagnosis was linked directly to the patient samples contributed by the participating countries, we were able to compensate for this to some degree by taking cluster sampling into account. Nevertheless, we acknowledge that some patient populations (eg, head-and-neck cancer) were overrepresented, and others may have been underrepresented in our sample.

Conclusion

In conclusion, our results provide empirical support for a measurement model for the QLQ-C30 that yields a single summary score based on 13 scales (27 items). The validity and responsiveness of the new summary score is equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores. Although not being a substitute for the individual scales, the availability of the QLQ-C30 summary score can reduce the risk of type I errors that can occur when making comparisons on the basis of the 15 outcomes generated by this questionnaire. In addition, use of the QLQ-C30 summary score can reduce sample size requirements. At the same time, there is some debate about

the appropriateness of using summary scores in certain research contexts, for example, in confirmatory clinical trials conducted to support product labeling claims [36,37]. However, these concerns may be more justified when a summary score is created on an ad hoc basis for a particular clinical trial. Ultimately, the research question and context should drive decisions regarding the optimal level of questionnaire data aggregation or disaggregation.

Although further testing and use in both observational studies and clinical trials is encouraged, the EORTC Quality of Life Group considers the current results to be sufficiently robust to recommend, provisionally, the use of the QLQ-C30 summary score to supplement the 15-outcome profile generated by the QLQ-C30. The exact scoring algorithm for generating the QLQ-C30 summary score is available via the group's Web site, <http://groups.eortc.be/qol>.

Acknowledgments

The authors would like to express their gratitude to many individuals who provided the data used in these analyses, and to Chad Gundy (deceased) who played a key role in the design and execution of the original study investigating the higher order scale structure of the QLQ-C30.

Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.jclinepi.2015.08.007>.

References

- [1] Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
- [2] Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: EORTC; 2001.
- [3] Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? *BMJ* 2001;322:989–91.
- [4] Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. *Psychol Sci* 2011;22:1359–66.
- [5] King MT, Bell ML, Costa D, Butow P, Oh B. The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. *J Clin Epidemiol* 2014; 67:100–7.
- [6] Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antràs L, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. *Eur J Cancer* 2012;48:311–23.
- [7] Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. *J Clin Oncol* 2013;31: 247–55.

- [8] Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. *Cancer* 2013;119:1908–15.
- [9] Raykov T. Behavioral scale reliability and measurement invariance evaluation using latent variable modeling. *Behav Ther* 2004;35:299–331.
- [10] Gundy CM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, et al. Comparing higher order models for the EORTC QLQ-C30. *Qual Life Res* 2012;21:1607–17.
- [11] Hinz A, Einenkel J, Briest S, Stolzenburg JU, Papsdorf K, Singer S. Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30? *Eur J Cancer Care (Engl)* 2012;21:677–83.
- [12] Nordin K, Steel J, Hoffman K, Glimelius B. Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. *Br J Cancer* 2001;85:1265–72.
- [13] Ware JE Jr, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. *J Clin Epidemiol* 1998;51:1159–65.
- [14] Güthlin C, Walach H. MOS-SF 36: structural equation modeling to test the construct validity of the second-order factor structure. *Eur J Psychol Assess* 2007;23(1):15–23.
- [15] Hays R, Bjorner J, Revicki D, Spritzer K, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. *Qual Life Res* 2009;18:873–80.
- [16] Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. *Med Care* 2007;45:S3–11.
- [17] Scott NW, Fayers PM, Bottomley A, Aaronson NK, Graeff A, Groenvold M, et al. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. *Qual Life Res* 2006;15:1103–15.
- [18] Scott NW, Fayers PM, Aaronson NK, Bottomley A, Graeff A, Groenvold M, et al. The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30. *Qual Life Res* 2007;16:115–29.
- [19] Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. *JAMA* 1995;273:59–65.
- [20] Pagano IS, Gotay CC. Modeling quality of life in cancer patients as a unidimensional construct. *Hawaii Med J* 2006;65:76–80. 82-5.
- [21] Boehmer S, Luszczyńska A. Two kinds of items in quality of life instruments: 'indicator and causal variables' in the EORTC qlq-c30. *Qual Life Res* 2006;15:131–41.
- [22] Fayers PM, Hand DJ. Factor analysis, causal indicators and quality of life. *Qual Life Res* 1997;6:139–50.
- [23] Muthén LK, Muthén BO. *Mplus User's Guide*. 6th ed. Los Angeles, CA: Muthén & Muthén; 1998-2007.
- [24] Hjerstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. *J Clin Oncol* 1995;13:1249–54.
- [25] Muthen B, du Toit S, Spisic D. *Robust Inference using Weighted Least Squares and Quadratic Estimating Equation in Latent Variable Modeling with Categorical and Continuous Outcomes* 1997. Available at http://www.statmodel.com/bmuthen/articles/Article_075.pdf Accessed January 8, 2015.
- [26] Flora D, Curran P. An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. *Psychol Methods* 2004;9:466.
- [27] Hu Lt, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. *Struct Equ Modeling* 1999;6:1–55.
- [28] Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. *Meth Psychol Res* 2003;8(2):23–74.
- [29] Ferguson E, Cox T. *Exploratory factor analysis: a Users' Guide*. *Int J Select Assess* 1993;1:84–94.
- [30] Cohen J. *Statistical power analysis for the behavioural sciences*. New York: Academic Press; 1977.
- [31] Fayers P, Hays R. *Assessing quality of life in clinical trials—methods and practice*. Oxford: Oxford University Press; 2005.
- [32] Raczek AE, Ware JE, Bjorner JB, Gandek B, Haley SM, Aaronson NK, et al. Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: results from the IQOLA Project. *J Clin Epidemiol* 1998;51:1203–14.
- [33] Lei P-W, Wu Q. Introduction to structural equation modeling: issues and practical considerations. *Educ Meas* 2007;26(3):33–43.
- [34] Costet N, Lapiere V, Benhamou E, Le Gales C. Reliability and validity of the Functional Assessment of Cancer Therapy General (FACT-G) in French cancer patients. *Qual Life Res* 2005;14:1427–32.
- [35] Dapuelto J, Francolino C, Servente L, Chang C-H, Gotta I, Levin R, et al. Evaluation of the functional assessment of Cancer Therapy-General (FACT-G) Spanish Version 4 in South America: classic psychometric and item response theory analyses. *Health Qual Life Outcomes* 2003;1:32.
- [36] US Department of Health and Human Services. *Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims* 2009. Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory/Information/Guidances/UCM193282.pdf Accessed January 8, 2015.
- [37] DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). *Value Health* 2013;16:1150–5.